中药熏洗防治希罗达所致手足综合征25例被引量：4

在线阅读下载PDF

导出

摘要目的观察中药熏洗防治希罗达相关性手足综合征的临床疗效。方法选择乳腺癌化疗患者25例,自口服希罗达化疗第1周期结束后,采用中药熏洗手足至化疗结束后7 d。结果25例患者中3例发生Ⅰ级手足综合征,发生率为12%。结论中药熏洗可使患者对希罗达化疗耐受性提高,对手足综合征有较好的防治作用。

作者张永军孙在典孔祥鸣张爱琴王晓稼陈占红

机构地区浙江省肿瘤医院浙江省中医院

出处《现代中西医结合杂志》 CAS 2008年第10期1495-1496,共2页 Modern Journal of Integrated Traditional Chinese and Western Medicine

关键词中药希罗达手足综合征

分类号 R730.53 [医药卫生—肿瘤]

引文网络
相关文献

参考文献11

1Blum JL, Jones SE, Buzdar AU, et al. Mulficenter phase Ⅱ study of capecitabinein paclitaxel-refractory metastatic breast cancer[J]. J Clin Oncol, 1999,12:485 - 493
2Abushullaih S, Saad ED, Munsell M, et al. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience [ J ]. Cancer Invest, 2002,20(1) :3 - 10
3刘冬耕,管忠震,宋三泰,刘晓晴,冯奉仪,张频,董梅,许立功,印季良,于世英,陈元.希罗达对晚期乳腺癌患者二线化疗临床研究[J].癌症,2001,20(12):1405-1407. 被引量：35
4王涛,江泽飞,宋三泰,申戈,张少华,张志强,曾敏.希罗达治疗乳腺癌所致手足综合征的发生规律及临床处理[J].癌症进展,2004,2(4):258-260. 被引量：67
5Katona C, Kralovanszky J, Rosta A, et al. Putativeroleof dihydropyri-cnidine dehydrogenase in the toxicside effect of 5 - fluoronracil in colorectal cancer patients[ J ]. Oncology, 1998,55 (5) : 468 - 474
6孙燕周际昌.临床肿瘤内科手册[M]3版[M].北京:人民卫生出版社,1996.30.
7Lin EH, Morris J, Chau NK, et al. Celecoxib attenuated capecitabine induced hand-and-foot syndrome(HFS) and diarrhea and improved time to tumor progression in metastatic coloreetal cancer (MCRC) [J]. Oncology,2002,21:2364
8郭中宁,杨宇飞.中药护胃愈肤汤治疗希罗达相关性手足综合征33例[J].中国肿瘤,2005,14(9):625-627. 被引量：24
9常忠莲,万冬桂.加味补阳还五汤防治希罗达所致手足综合征45例[J].中国中医药信息杂志,2005,12(6):63-64. 被引量：25
10王玲,焦智民,李平.中药内服外洗治疗希罗达所致中重度手足综合征8例[J].中医研究,2006,19(4):41-43. 被引量：39

二级参考文献30

1王涛,江泽飞,宋三泰,申戈,张少华,张志强,曾敏.希罗达治疗乳腺癌所致手足综合征的发生规律及临床处理[J].癌症进展,2004,2(4):258-260. 被引量：67
2王涛,江泽飞,宋三泰,张少华,申戈,于静新.单药希罗达治疗复发转移性乳腺癌的疗效观察[J].中华肿瘤杂志,2004,26(6):379-381. 被引量：57
3梅华.希罗达联合奥沙利铂治疗晚期结直肠癌的临床观察[J].实用临床医学（江西）,2005,6(5):5-6. 被引量：11
4[1]Budman DR, Meropol NJ, Reiger B, et al. Preliminary studies of a novel fluoropyrimidine carbamate: Capecitabine [J]. J Clin Oncol, 1998, 16: 1795-1802.
5[2]Mackean MJ, Planting AS, Twelves C, et al. A Phase I and pharmacologic study of intermittent twice daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer [J]. J Clin Oncol, 1998, 16: 2977-2985.
6[1]Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol, 1999, 17 (2):485
7[2]Talbot DC, Moiseyenko V, Van Belle S, et al. Randomised,phase Ⅱ trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreatedwith anthracyclines. Br J Cancer, 2002, 86 (9):1367
8[3]Meta-analysis goup in cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced coleorectal cancer. J Clin Oneol. 1998, 16:301
9[4]Meta-analysis group in carcer. Toxicity of fiuorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. J Clin Oncol, 1998, 16:3537
10[5]Lokich JJ, Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Inter Med, 1984, 101 :798